Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomization was performed by a person who was not a study interviewer or therapist using a SAS procedure and was stratified by patient performance status (self-reported ECOG scores 0 or 1 vs. 2) because this factor informs cancer treatment decision-making [33].”
From Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial (2018) · cites this paper as [33]
In the citing paper
“We are stratifying randomization by performance status because it is a key factor in MBC treatment decisions [28].”
From Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer (2020) · cites this paper as [28]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Research works printed but not linked: 1
- Network NCC. 2008. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2, ASCO-Edition 2008.
Cited by
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., Minisini, A. M., Andreetta, C., Mansutti, M., Pisa, F. E., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0002 · Cited by 295
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer
Diot, G., Metz, S., Noske, A., Liapis, E., Schroeder, B., Ovsepian, S. V., Meier, R., Rummeny, E., & Ntziachristos, V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3200 · Cited by 270
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
van Kruchten, M., de Vries, E. G., Glaudemans, A. W., van Lanschot, M. C., van Faassen, M., Kema, I. P., Brown, M., Schröder, C. P., de Vries, E. F., & Hospers, G. A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0697 · Cited by 224
Datta, N. R., Puric, E., Klingbiel, D., Gomez, S., & Bodis, S. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.12.361 · Cited by 220
Twelves, C., Cortes, J., Vahdat, L., Olivo, M., He, Y., Kaufman, P. A., & Awada, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3144-y · Cited by 217
18F-FDG PET/CT for Staging and Restaging of Breast Cancer
Groheux, D., Cochet, A., Humbert, O., Alberini, J.-L., Hindié, E., & Mankoff, D. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157859 · Cited by 201
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
Mucaki, E. J., Zhao, J. Z. L., Lizotte, D. J., & Rogan, P. K. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0034-5 · Cited by 200
Lehrer, E. J., Singh, R., Wang, M., Chinchilli, V. M., Trifiletti, D. M., Ost, P., Siva, S., Meng, M.-B., Tchelebi, L., & Zaorsky, N. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6146 · Cited by 196
Petricevic, B., Laengle, J., Singer, J., Sachet, M., Fazekas, J., Steger, G., Bartsch, R., Jensen-Jarolim, E., & Bergmann, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-307 · Cited by 192
Bevacizumab: A Review of Its Use in Advanced Cancer
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 177
Combating subclonal evolution of resistant cancer phenotypes
Brady, S. W., McQuerry, J. A., Qiao, Y., Piccolo, S. R., Shrestha, G., Jenkins, D. F., Layer, R. M., Pedersen, B. S., Miller, R. H., Esch, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01174-3 · Cited by 163
Burnett, J., Lim, G., Li, Y., Shah, R. B., Lim, R., Paholak, H. J., McDermott, S., Sun, L., Tsume, Y., Bai, S., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.023 · Cited by 169
Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S., Masuda, N., Loi, S., André, F., Harbeck, N., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0072 · Cited by 156
Self-citationClinical and molecular complexity of breast cancer metastases
Kimbung, S., Loman, N., & Hedenfalk, I. A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.009 · Cited by 170
Zhong, Y., Peng, Z., Peng, Y., Li, B., Pan, Y. H., Ouyang, Q., Sakiyama, H., Muddassir, M., & Liu, J. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00749a · Cited by 148
Tao, X., Yin, L., Xu, L., & Peng, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.022 · Cited by 156
Zhang, Y., Cheng, S., Zhang, M., Zhen, L., Pang, D., Zhang, Q., & Li, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076147 · Cited by 140
RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer
Sun, C., Li, S., Hu, W., Zhang, J., Zhou, Q. Y., Liu, C., Li, L., Songyang, Y., Zhang, F., Chen, Z., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.019 · Cited by 140
“with breast cancer, of which only one-fifth survive 5 years.(13) Due to tumor heterogeneity, the current biomarkers that predict prognosis have some limitations, and, thus, the field needs new biomarkers as prognostic indicators to effectively enhance prognosis and individualized treatment.”
BackgroundRetractedCorbeau, I., Jacot, W., & Guiu, S. (2020) · Cancers · doi:10.3390/cancers12040958 · Cited by 153
The role of taxanes in triple-negative breast cancer: literature review
Mustacchi, G., & Laurentiis, M. D. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86105 · Cited by 150
The NF-KB pathway and endocrine therapy resistance in breast cancer
Khongthong, P., Roseweir, A. K., & Edwards, J. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0087 · Cited by 164
Zagouri, F., Sergentanis, T. Ν., Bartsch, R., Berghoff, A. S., Chrysikos, D., de Azambuja, E., Dimopoulos, M. A., & Preusser, M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2525-y · Cited by 133
Prat, A., Cheang, M. C. U., Galván, P., Nuciforo, P., Paré, L., Adamo, B., Muñoz, M., Viladot, M., Press, M. F., Gagnon, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0922 · Cited by 132
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers
Li, Y., Zhao, B., Peng, J., Tang, H., Wang, S., Peng, S., Ye, F., Wang, J., Ouyang, K., Li, J., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101042 · Cited by 151
The role of the GP in follow-up cancer care: a systematic literature review
Meiklejohn, J. A., Mimery, A., Martin, J. H., Bailie, R. S., Garvey, G., Walpole, E. T., Adams, J., Williamson, D. S., & Valery, P. C. (2016) · Journal of Cancer Survivorship · doi:10.1007/s11764-016-0545-4 · Cited by 127
Dorman, S. N., Baranova, K., Knoll, J. H. M., Urquhart, B. L., Mariani, G., Carcangiu, M. L., & Rogan, P. K. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.07.006 · Cited by 121
Liu, K., Zhang, W., Dai, Z., Wang, M., Tian, T., Liu, X., Kang, H., Guan, H., Zhang, S., & Dai, Z. (2018) · Cancer Management and Research · doi:10.2147/cmar.s144619 · Cited by 135
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu524 · Cited by 114
Jiang, K., Lü, Q., Li, Q., Ji, Y.-J., Chen, W., & Xue, X. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.10.001 · Cited by 112
In vitro assays and techniques utilized in anticancer drug discovery
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3658 · Cited by 130
“In metastasis, cancer cells move away from primary tumors and travel through the blood and lymphatic system and form new tumors on other parts (Cardoso et al., 2012; Chambers et al., 2002).”
BackgroundGao, F., Zhang, J., Fu, C., Xie, X., Peng, F., You, J., Tang, H., Wang, Z., Li, P., & Chen, J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s134148 · Cited by 108
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer
Vaz, S. C., Woll, J. P. P., Cardoso, F., Groheux, D., Cook, G., Ulaner, G. A., Jacene, H. A., Rubio, I. T., Schoones, J. W., Peeters, M.-J. T. F. D. V., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06696-9 · Cited by 130
Self-citationYeung, C., Hilton, J. F., Clemons, M. J., Mazzarello, S., Hutton, B., Haggar, F. A., Addison, C., Kuchuk, I., Zhu, X., Gelmon, K. A., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9631-3 · Cited by 120
Liu, K., Xie, F., Gao, A., Zhang, R., Zhang, L., Xiao, Z., Hu, Q., Huang, W., Huang, Q., Lin, B., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0632-9 · Cited by 110
Muchtaridi, M., Syahidah, H. N., Subarnas, A., Yusuf, M., Bryant, S. D., & Langer, T. (2017) · Pharmaceuticals · doi:10.3390/ph10040081 · Cited by 121
Mosher, C. E., Secinti, E., Li, R., Hirsh, A. T., Bricker, J., Miller, K. D., Schneider, B., Storniolo, A. M., Mina, L., Newton, E. V., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4045-0 · Cited by 95
Takashima, T., Mukai, H., Hara, F., Matsubara, N., Saito, T., Takano, T., Park, Y., Toyama, T., Hozumi, Y., Tsurutani, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00411-8 · Cited by 101
Subcutaneous Administration of Monoclonal Antibodies in Oncology
Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0034-1368173 · Cited by 90
Adams, S., Dieras, V. C., Barrios, C. H., Winer, E. P., Schneeweiß, A., Iwata, H., Loi, S., Patel, S., Henschel, V., Chui, S. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.003 · Cited by 94
Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer
Warschkow, R., Güller, U., Tarantino, I., Cerny, T., Schmied, B. M., Thuerlimann, B., & Joerger, M. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001302 · Cited by 90
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
Beck, J. T., Hortobágyi, G. N., Campone, M., Lebrun, F., Deleu, I., Rugo, H. S., Pistilli, B., Masuda, N., Hart, L. L., Melichar, B., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2814-5 · Cited by 91
Yuan, P., Hu, X., Sun, T., Li, W., Zhang, Q., Cui, S., Cheng, Y., Ouyang, Q., Wang, X., Chen, Z., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.02.002 · Cited by 89
Cardoso, F., Bese, N., Distelhorst, S. R., Bevilacqua, J. L. B., Ginsburg, O., Grunberg, S. M., Gralla, R. J., Steyn, A., Pagani, O., Partridge, A. H., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.050 · Cited by 83
Self-citationRecent advances in liposome formulations for breast cancer therapeutics
Yang, B., Song, B.-P., Shankar, S., Guller, A., & Deng, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03850-6 · Cited by 87
“In this context, gene therapy is emerging to revolutionize the classic breast cancer treatment paradigm [8].”
BackgroundSalmonella -Mediated Cancer Therapy: An Innovative Therapeutic Strategy
Mi, Z., Feng, Z., Li, C., Yang, X. H., Ma, M., & Rong, P. (2019) · Journal of Cancer · doi:10.7150/jca.32650 · Cited by 83
Hua, X., Bi, X.-W., Zhao, J.-L., Shi, Y.-X., Lin, Y., Wu, Z.-Y., Zhang, Y.-Q., Zhang, L.-H., Zhang, A.-Q., Huang, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3435 · Cited by 75
Swallow, E., Zhang, J., Thomason, D., Tan, R., Kageleiry, A., & Signorovitch, J. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.908829 · Cited by 69
Amin, K. M., Syam, Y. M., Anwar, M. M., Ali, H. I., Abdel-Ghani, T. M., & Serry, A. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.12.029 · Cited by 67
Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., & Marschner, N. (2017) · The Breast · doi:10.1016/j.breast.2017.05.014 · Cited by 65
Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results
Golse, N., & Adam, R. A. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.12.012 · Cited by 65
Triple Negative Breast Cancer: Nanosolutions for a Big Challenge
Mendes, T. S., Kluskens, L., & Rodrigues, L. R. (2015) · Advanced Science · doi:10.1002/advs.201500053 · Cited by 67
Cleary, J. F., Ddungu, H., Distelhorst, S. R., Ripamonti, C. I., Rodin, G., Bushnaq, M. A., Clegg‐Lamptey, J., Connor, S. R., Diwani, M., Eniu, A. E., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.052 · Cited by 72
Chung, C., & Christianson, M. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212474047 · Cited by 68
Cardoso, F., Harbeck, N., Mertz, S. A., & Fenech, D. (2016) · The Breast · doi:10.1016/j.breast.2016.04.004 · Cited by 61
Self-citationKuemmel, S., Campone, M., Loirat, D., López‐López, R., Beck, J. T., Laurentiis, M. D., Im, S., Kim, S.-B., Kwong, A., Steger, G. G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3955 · Cited by 63
Chang, W. T., Lai, T.-H., Chyan, Y., Yin, S. Y., Chen, Y., Wei, W. C., & Yang, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122374 · Cited by 63
Beije, N., Onstenk, W., Kraan, J., Sieuwerts, A. M., Hamberg, P., Dirix, L. Y., Brouwer, A., de Jongh, F. E., Jager, A., Seynaeve, C., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.007 · Cited by 60
Berghoff, A. S., Bartsch, R., Wöehrer, A., Streubel, B., Birner, P., Kros, J. M., Brastianos, P. K., von Deimling, A., & Preusser, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1350-7 · Cited by 61
Staudigl, C., Concin, N., Grimm, C., Pfeiler, G., Nehoda, R., Singer, C. F., & Polterauer, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125317 · Cited by 54
Crozier, J. A., Advani, P. P., LaPlant, B. R., Hobday, T. J., Jaslowski, A. J., Moreno‐Aspitia, A., & Perez, E. A. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.08.002 · Cited by 57
Kimbung, S., Johansson, I., Danielsson, A., Veerla, S., Brage, S. E., Stolt, M. F., Skoog, L. K., Carlsson, L. M. S., Einbeigi, Z., Lidbrink, E. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0487 · Cited by 58
Seneviratne, S. A., Lawrenson, R. A., Harvey, V. J., Ramsaroop, R., Elwood, M., Scott, N., Sarfati, D., & Campbell, I. (2016) · BMC Cancer · doi:10.1186/s12885-016-2177-5 · Cited by 53
MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A.
Wang, B., Yang, Z., Wang, H., Cao, Z., Zhao, Y., Gong, C., Ma, L., Wang, X., Hu, X., & Chen, S. (2015) · Europe PMC (PubMed Central) · Cited by 52
Hoefnagel, L. D. C., van der Groep, P., van de Vijver, M. J., Boers, J. E., Wesseling, P., Wesseling, J., van der Wall, E., & van Diest, P. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt390 · Cited by 51
Stenvang, J., Kümler, I., Nygård, S. B., Smith, D. H., Nielsen, D., Brünner, N., & Moreira, J. M. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00313 · Cited by 51
Fan, J., Chen, D., Du, H., Shen, C., & Che, G. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.08.10 · Cited by 62
Schröder, J., Fietz, T. J., Köhler, A., Petersen, V., Tesch, H., Spring, L., Fleitz, A., Jänicke, M., & Marschner, N. W. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.031 · Cited by 53
Müller, H. D., Posch, F., Suppan, C., Bargfrieder, U., Gumpoldsberger, M., Hammer, R. E., Häuser, H., Dandachi, N., Prein, K., Stoeger, H., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07741-w · Cited by 53
Li, Z., Dong, J., Zou, T., Du, C., Li, S., Chen, C., Liu, R., & Wang, K. (2016) · Oncotarget · doi:10.18632/oncotarget.14135 · Cited by 50
Kaklamani, V., & Gradishar, W. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2015-0464 · Cited by 53
Kawalec, P., Łopuch, S., & Mikrut, A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.10.006 · Cited by 52
André, F., Neven, P., Marinsek, N., Zhang, J., Baladi, J., Degun, R., Benelli, G., Saletan, S., & Jérusalem, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.887002 · Cited by 49
Onstenk, W., Sieuwerts, A. M., Weekhout, M., Mostert, B., Reijm, E. A., van Deurzen, C. H. M., Vries, J. B., Peeters, D. J. E., Hamberg, P., Seynaeve, C., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.020 · Cited by 54
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Başaran, G., Twelves, C. J., Dieras, V. C., Cortés, J., & Awada, A. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.002 · Cited by 51
Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer
Yu, H., Li, H., Qian, H., Jiao, X., Zhu, X., Jiang, X., Dai, G., & Huang, J. (2014) · Medical Oncology · doi:10.1007/s12032-014-0283-2 · Cited by 47
ConfidentCare: A Clinical Decision Support System for Personalized Breast Cancer Screening
Alaa, A. M., Moon, K. H., Hsu, W., & van der Schaar, M. (2016) · IEEE Transactions on Multimedia · doi:10.1109/tmm.2016.2589160 · Cited by 47
Mertens, L. S., Mir, M. C., Scott, A. M., Lee, S. T., Fioole‐Bruining, A., Vegt, E., Vogel, W. V., Manecksha, R. P., Bolton, D. M., Davis, I. D., et al. (2014) · Urology · doi:10.1016/j.urology.2013.10.032 · Cited by 47
Llombart‐Cussac, A., Pivot, X. B., Biganzoli, L., Cortés-Funes, H., Pritchard, K. I., Pierga, J., Smith, I., Thomssen, C., Srock, S., Sampayo, M., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.06.017 · Cited by 49
Dranitsaris, G., King, J., Kaura, S., Yu, B., & Zhang, A. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s82194 · Cited by 45
Inoue, K., Saito, T., Okubo, K., Kimizuka, K., Yamada, H., Sakurai, T., Ishizuna, K., Hata, S., Kai, T., & Kurosumi, M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3808-x · Cited by 46
Gupta, S., Zhang, J., & Jérusalem, G. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.949243 · Cited by 46
Tabouret-Viaud, C., Botsikas, D., Delattre, B. M. A., Mainta, I., Amzalag, G., Rager, O., Vinh‐Hung, V., Miralbell, R., & Ratib, O. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.03.003 · Cited by 43
Walsh, L. A., Roy, D. M., Reyngold, M., Giri, D. D., Snyder, A., Turcan, Ş., Badwe, C. R., Lyman, J., Bromberg, J., King, T. A., et al. (2014) · Oncogene · doi:10.1038/onc.2014.175 · Cited by 45
Kimbung, S., Kovács, A., Danielsson, A., Bendahl, P., Lövgren, K., Stolt, M. F., Tobin, N. P., Lindström, L. S., Bergh, J. C. S., Einbeigi, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5089 · Cited by 43
McFall, T. B., McKnight, B. N., Rosati, R., Kim, S., Huang, Y., Viola, N. T., & Ratnam, M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.812438 · Cited by 51
Cai, H., Li, J., Gu, B., Xiao, Y., Chen, R., Liu, X., Xie, X., & Cao, L. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.12.012 · Cited by 42
De-implementing low-value care in cancer care delivery: a systematic review
Tabriz, A. A., Turner, K. L., Clary, A., Hong, Y., Nguyen, O. T., Wei, G., Carlson, R., & Birken, S. A. (2022) · Implementation Science · doi:10.1186/s13012-022-01197-5 · Cited by 53
“For example, both the American Society for Clinical Oncology and Choosing Wisely Canada [15,16] recommend not to use imaging in early-stage breast cancer; despite these recommendations, about one-third of early-stage breast cancer patients underwent at least one advanced imaging exam (e.g., bone scan, positron-emissio…”
BackgroundMontigaud, Y., Učakar, B., Krishnamachary, B., Bhujwalla, Z. M., Féron, O., Véronique Préat, A., Danhier, F., Gallez, B., & Danhier, P. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.09.034 · Cited by 45
Autophagy in breast cancer metastatic dormancy: tumor suppressing or tumor promoting functions?
Flynn, A. L. B., & Schiemann, W. P. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.13 · Cited by 44
miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer
Yang, F., Li, Y., Xu, L., Zhu, Y., Gao, H., Lin, Z., & Fang, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s127723 · Cited by 41
4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
Marchi, T. D., Liu, N. Q., Stingl, C., Timmermans, M. A. M., Smid, M., Look, M. P., Tjoa, M., Braakman, R. B. H., Opdam, M., Linn, S. C., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.07.004 · Cited by 42
Biganzoli, L., Lichtman, S. M., Michel, J.-P., Papamichael, D., Quoix, É., Walko, C. M., & Aapro, M. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.005 · Cited by 47
Palumbo, R., Sottotetti, F., Trifirò, G., Piazza, E., Ferzi, A., Gambaro, A., Spinapolice, E. G., Pozzi, E., Tagliaferri, B., Teragni, C. M., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79563 · Cited by 43
Whole-Body Magnetic Resonance Imaging in Oncology
Petralia, G., & Padhani, A. R. (2018) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2018.06.003 · Cited by 41
Wang, L., Cao, J., Li, C., Wang, X., Zhao, Y., Li, T., Du, Y., Tao, Z., Peng, W., Wang, B., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01182-7 · Cited by 38
“Despite advances in early diagnosis, 5–10% of newly diagnosed breast cancer patients were with latestage presentation and metastasis [2].”
BackgroundYeo, H. Y., Liew, A. C., Chan, S. J., Anwar, M., Han, C. H., & Marra, C. A. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s432821 · Cited by 46
Metadata
- Authors
- Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E.
- Affiliations
- European School of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Gdańsk Medical University (PL)
- Corresponding author
- Senkus, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 23
- Pages
- vii11-vii19
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4234749243
- Cited by
- 485
- References
- 40
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 30 · 2020: 37 · 2019: 41 · 2018: 33 · 2017: 53 · 2016: 42 · 2015: 66 · 2014: 49 · 2013: 32 · 2012: 1
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2625 d)
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- locally recurrent breast cancer, metastatic breast cancer, breast cancer diagnosis, breast cancer treatment, breast cancer follow-up, incidence, mortality, early detection, adjuvant systemic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.